Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 2
1976 2
1977 8
1978 13
1979 38
1980 16
1981 15
1982 22
1983 23
1984 18
1985 19
1986 17
1987 22
1988 19
1989 15
1990 15
1991 13
1992 15
1993 16
1994 15
1995 12
1996 10
1997 16
1998 15
1999 18
2000 15
2001 19
2002 14
2003 10
2004 18
2005 25
2006 20
2007 19
2008 19
2009 18
2010 24
2011 26
2012 43
2013 42
2014 62
2015 57
2016 51
2017 58
2018 56
2019 67
2020 81
2021 65
2022 71
2023 68
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

1,259 results

Results by year

Filters applied: . Clear all
Page 1
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Strzelczyk A, Schubert-Bast S. Strzelczyk A, et al. CNS Drugs. 2022 Oct;36(10):1079-1111. doi: 10.1007/s40263-022-00955-9. Epub 2022 Oct 4. CNS Drugs. 2022. PMID: 36194365 Free PMC article. Review.
We have performed a targeted literature review of ASMs commonly used in the treatment of developmental and epileptic encephalopathies to discuss the latest evidence on their effects on behaviour, mood, cognition, sedation and sleep. The ASMs include valproate (VPA), clobazam
We have performed a targeted literature review of ASMs commonly used in the treatment of developmental and epileptic encephalopathies to dis …
Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Montouris G, Aboumatar S, Burdette D, Kothare S, Kuzniecky R, Rosenfeld W, Chung S. Montouris G, et al. Epilepsy Behav. 2020 Sep;110:107146. doi: 10.1016/j.yebeh.2020.107146. Epub 2020 Jun 18. Epilepsy Behav. 2020. PMID: 32563898 Free article. Review.
ASDs were categorized based on order of preference for use in the treatment of LGS; Tier 1 comprises recommended first-line ASDs, and includes valproate, clobazam, lamotrigine, rufinamide, topiramate, and cannabidiol. Other treatment options include diet, neurostimulation, …
ASDs were categorized based on order of preference for use in the treatment of LGS; Tier 1 comprises recommended first-line ASDs, and includ …
A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A, Schubert-Bast S. Strzelczyk A, et al. CNS Drugs. 2022 Mar;36(3):217-237. doi: 10.1007/s40263-022-00898-1. Epub 2022 Feb 14. CNS Drugs. 2022. PMID: 35156171 Free PMC article.
Initial treatments include the broad-spectrum ASMs valproate (VPA), and clobazam (CLB) in some regions; however, they are generally insufficient to control seizures. ...
Initial treatments include the broad-spectrum ASMs valproate (VPA), and clobazam (CLB) in some regions; however, they are generally i …
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A, Estes E, Aparasu R, Reddy DS. Talwar A, et al. Exp Neurol. 2023 Jan;359:114238. doi: 10.1016/j.expneurol.2022.114238. Epub 2022 Oct 4. Exp Neurol. 2023. PMID: 36206805
A subgroup analysis by syndrome and CBD with or without concomitant clobazam was conducted. The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy. ...In conclusion, the …
A subgroup analysis by syndrome and CBD with or without concomitant clobazam was conducted. The key outcomes were reduction in seizur …
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K; GWPCARE1 Part A Study Group. Devinsky O, et al. Neurology. 2018 Apr 3;90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14. Neurology. 2018. PMID: 29540584 Free PMC article. Clinical Trial.
Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites 6-OH-CBD, 7-OH-CBD, and 7-COOH-CBD, and antiepileptic drugs (AEDs; clobazam and metabolite N-desmethylclobazam [N-CLB], valproate, l …
Multiple pharmacokinetic blood samples were taken on the first day of dosing and at end of treatment for measurement of CBD, its metabolites …
Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*).
van den Munckhof B, Arzimanoglou A, Perucca E, van Teeseling HC, Leijten FSS, Braun KPJ, Jansen FE; RESCUE ESES study group. van den Munckhof B, et al. Trials. 2020 Nov 23;21(1):957. doi: 10.1186/s13063-020-04874-2. Trials. 2020. PMID: 33228736 Free PMC article. Clinical Trial.
Based on mostly small and retrospective studies, corticosteroids and clobazam are regarded by many clinicians as the most effective pharmacological treatments. This European multicentre randomised controlled trial is designed to compare the effects of corticosteroids and …
Based on mostly small and retrospective studies, corticosteroids and clobazam are regarded by many clinicians as the most effective p …
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, Kochen S, Meador KJ, Pennell PB, Thomas SV. Tomson T, et al. Epileptic Disord. 2022 Dec 1;24(6):1020-1032. doi: 10.1684/epd.2022.1492. Epileptic Disord. 2022. PMID: 36193017 Free article. English.
No data on ASM levels in breastmilk or in breastfed infants was identified for cannabidiol, cenobamate, clobazam, eslicarbazepine-acetate, everolimus, felbamate, fenfluramine, retigabine, rufinamide, stiripentol, tiagabine, and vigabatrin. ...
No data on ASM levels in breastmilk or in breastfed infants was identified for cannabidiol, cenobamate, clobazam, eslicarbazepine-ace …
Clobazam.
Ng YT, Collins SD. Ng YT, et al. Neurotherapeutics. 2007 Jan;4(1):138-44. doi: 10.1016/j.nurt.2006.11.002. Neurotherapeutics. 2007. PMID: 17199029 Free PMC article. Review.
This review will explore the use of clobazam in the treatment of epilepsy, particularly with regard to its potential benefit in LGS. ...A phase 2 study will be completed in late 2006 to investigate the safety and efficacy of clobazam as adjunctive therapy in 68 pedi …
This review will explore the use of clobazam in the treatment of epilepsy, particularly with regard to its potential benefit in LGS. …
PharmGKB summary: clobazam pathway, pharmacokinetics.
Huddart R, Leeder JS, Altman RB, Klein TE. Huddart R, et al. Pharmacogenet Genomics. 2018 Apr;28(4):110-115. doi: 10.1097/FPC.0000000000000327. Pharmacogenet Genomics. 2018. PMID: 29517622 Free PMC article. No abstract available.
Clobazam monotherapy for focal or generalized seizures.
Arya R, Giridharan N, Anand V, Garg SK. Arya R, et al. Cochrane Database Syst Rev. 2018 Jul 11;7(7):CD009258. doi: 10.1002/14651858.CD009258.pub3. Cochrane Database Syst Rev. 2018. PMID: 29995989 Free PMC article. Review.
There was low-quality evidence that clobazam led to better retention compared with phenytoin (RR 1.43, 95% CI 1.08 to 1.90). ...AUTHORS' CONCLUSIONS: We found no advantage for clobazam over carbamazepine for retention at 12 months in drug-naive children and a slight …
There was low-quality evidence that clobazam led to better retention compared with phenytoin (RR 1.43, 95% CI 1.08 to 1.90). ...AUTHO …
1,259 results